Optiver Holding
CADL icon

Optiver Holding’s Candel Therapeutics CADL Stock Holding History

Optiver Holding’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.72K Sell
264
-136
-34% -$1.03K ﹤0.01% 2215
2026
Q1 		$1.96K Sell
400
-256
-39% -$1.39K ﹤0.01% 1858
2025
Q4 		$3.71K Hold
656
– – ﹤0.01% 1587
2025
Q3 		$3.35K Buy
+656
New +$3.79K ﹤0.01% 2105

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Optiver Holding's CADL Position: Q2 2026 in Review

Optiver Holding reduced its Candel Therapeutics (CADL) stake by 34% in Q2 2026, selling an estimated $1.03K and leaving 264 shares worth $2.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Optiver Holding first reported a position in CADL in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.71K in Q4 2025. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Optiver Holding held 264 shares of Candel Therapeutics worth $2.72K as of Q2 2026.
  • Optiver Holding sold 136 Candel Therapeutics shares in Q2 2026, an estimated $1.03K.
  • Candel Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2215 holding.
  • Optiver Holding first reported a position in Candel Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Candel Therapeutics position peaked at $3.71K in Q4 2025.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.